What's in Mylan Bertek Pharmaceuticals's pipeline?

Mylan Bertek Pharmaceuticals has 3 drugs in our index: 1 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Mylan Bertek Pharmaceuticals's portfolio?

Top competitors by shared drug class: Beijing Bozhiyin T&S Co., Ltd., Beth Israel Deaconess Medical Center, Britannia Pharmaceuticals Ltd., Desitin Arzneimittel GmbH, GlaxoSmithKline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mylan-bertek-pharmaceuticals.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Mylan Bertek Pharmaceuticals — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mylan Bertek Pharmaceuticals pipeline: 1 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Nebivolol (NEB)	Nebivolol (NEB)	marketed	Beta-1 selective adrenergic receptor antagonist	Beta-1 adrenergic receptor	Cardiovascular
Nebivolol and Atenolol	Nebivolol and Atenolol	phase 3	Beta-blocker (beta-1 selective adrenergic antagonist)	Beta-1 adrenergic receptor	Cardiovascular
apomorphine HCl injection	apomorphine HCl injection	phase 3	Dopamine agonist	Dopamine receptor	Neurology

Therapeutic area mix

Cardiovascular · 2
Neurology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Beijing Bozhiyin T&S Co., Ltd. · 1 shared drug class
Beth Israel Deaconess Medical Center · 1 shared drug class
Britannia Pharmaceuticals Ltd. · 1 shared drug class
Desitin Arzneimittel GmbH · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Intec Pharma Ltd. · 1 shared drug class
Leiden University Medical Center · 1 shared drug class
Axxonis Pharma AG · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mylan Bertek Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Mylan Bertek Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mylan-bertek-pharmaceuticals. Accessed 2026-05-16.